secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0000950170-23-049802
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma initiates Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD
--------------------------------------------------------------------------

- EFZO-CONNECT is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study in systemic sclerosis-associated ILD.
- Study enrolls 25 patients across multiple US centers; 28-week treatment with monthly IV doses of efzofitimod (270 mg or 450 mg) or placebo.
- Primary objective: evaluate efficacy of efzofitimod on pulmonary, cutaneous, and systemic manifestations in SSc-ILD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023049802/0000950170-23-049802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023049802/life-20230926.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-049802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer